Latest Insider Transactions at Natus Medical Inc (NTUS)
This section provides a real-time view of insider transactions for Natus Medical Inc (NTUS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NATUS MEDICAL INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NATUS MEDICAL INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 28
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
808
-1.52%
|
$21,008
$26.9 P/Share
|
|
May 27
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,467
-16.43%
|
$282,609
$27.1 P/Share
|
|
May 25
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,435
-12.9%
|
$254,745
$27.41 P/Share
|
|
May 24
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,000
-21.47%
|
$540,000
$27.11 P/Share
|
|
May 20
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,290
-9.07%
|
$250,830
$27.0 P/Share
|
|
May 19
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,367
-5.85%
|
$165,542
$26.54 P/Share
|
|
May 18
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,904
-2.6%
|
$75,504
$26.9 P/Share
|
|
May 14
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,927
-16.41%
|
$613,956
$28.31 P/Share
|
|
May 13
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
27,721
-17.18%
|
$748,467
$27.96 P/Share
|
|
May 12
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,108
-5.9%
|
$272,916
$27.47 P/Share
|
|
Apr 30
2021
|
Jonathan Kennedy President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
489
+0.25%
|
$10,269
$21.72 P/Share
|
|
Apr 30
2021
|
Austin Francis Noll Iii Executive VP and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
489
+0.4%
|
$10,269
$21.72 P/Share
|
|
Jan 04
2021
|
Austin Francis Noll Iii Executive VP and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
33,965
+21.92%
|
$679,300
$20.61 P/Share
|
|
Jan 04
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,835
+11.3%
|
$436,700
$20.61 P/Share
|
|
Jan 04
2021
|
Benjamin Drew Davies Executive VP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
20,622
+35.54%
|
$412,440
$20.61 P/Share
|
|
Jan 04
2021
|
Jonathan Kennedy President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
66,716
+25.86%
|
$1,334,320
$20.61 P/Share
|
|
Jan 02
2021
|
Austin Francis Noll Iii Executive VP and CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,704
-7.15%
|
$134,080
$20.04 P/Share
|
|
Jan 02
2021
|
Dong Chune Christopher Chung Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,263
-3.4%
|
$105,260
$20.04 P/Share
|
|
Jan 02
2021
|
Benjamin Drew Davies Executive VP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,670
-17.95%
|
$73,400
$20.04 P/Share
|
|
Jan 02
2021
|
Jonathan Kennedy President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,985
-10.74%
|
$299,700
$20.04 P/Share
|
|
Dec 31
2020
|
Benjamin Drew Davies Executive VP and CFO |
SELL
Other acquisition or disposition
|
Direct |
23,845
-53.83%
|
$476,900
$20.04 P/Share
|
|
Dec 31
2020
|
Jonathan Kennedy President and CEO |
SELL
Other acquisition or disposition
|
Direct |
22,695
-13.98%
|
$453,900
$20.04 P/Share
|
|
Oct 30
2020
|
Austin Francis Noll Iii Executive VP and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
686
+0.73%
|
$10,290
$15.48 P/Share
|
|
Oct 30
2020
|
Jonathan Kennedy President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
686
+0.42%
|
$10,290
$15.48 P/Share
|
|
Oct 01
2020
|
Benjamin Drew Davies Executive VP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,664
-5.67%
|
$45,288
$17.19 P/Share
|